Healthcare Private Placement and M&A Transactions Review Week Ending May 15 2022

Domain Therapeutics: The company raised EUR 39 million of Series A venture funding in a deal led by Panacea Venture, CTI Life Sciences Fund and 3B Future Health Ventures on May 10, 2022. adMare BioInnovations, Omnes Capital, Theodorus, Seventure Partners, Viva BioInnovator, Turenne Capital Partenaires and Schroders Capital also participated in the round. The company is a developer of medical therapeutics intended for the treatment of central nervous system (CNS) diseases and cancer.

AcuityMD: The company raised $31 million of Series A venture funding in a deal led by Redpoint Ventures on May 12, 2022. Benchmark, Ajax Health, Artisanal Ventures and other undisclosed investors also participated in the round. The company is a developer of healthcare software created to provide new ways of designing and marketing medical devices.

Q’Apel: The company raised $30 million of Series D venture funding from undisclosed investors on April 4, 2022, putting the company’s pre-money valuation at $91 million. The company is a developer of medical devices designed to help physicians overcome their challenges concerning the delivery of successful neurovascular procedures.

Artax Biopharma: The company raised $26 million of Series B4 venture funding in a deal led by Eli Lilly and Sound Bioventures on May 11, 2022, putting the company’s pre-money valuation at $32 million. Advent Life Sciences, Columbus Venture Partners and Belinda Termeer also participated in the round. The company is a developer of drugs intended to treat autoimmune and inflammatory diseases.

Therapixel: The company raised EUR 15 million of Series B venture funding in a deal led by Crédit Mutuel Innovation and CapHorn Invest on May 12, 2022. Sham Innovation Santé, M Capital Partners, Omnes Capital, Verve Equity Partners, IT-Translation and Région Sud Investissement also participated in the round. The company is a developer of a medical imaging technology intended to deliver pertinent information at the right time to healthcare professionals.

INCOG BioPharma Services: The company raised $15 million of venture funding through a combination of debt and equity from undisclosed investors on May 10, 2022. The company is an operator of a contract development and manufacturing organization intended to support biopharmaceutical partners’ clinical and commercial requirements.

Lirio: The company raised $14.4 million of venture funding from Bon Secours Mercy Health and Rochester Regional Health System on May 12, 2022. The company is an operator of a behavior change AI platform intended to unite behavioral science with artificial intelligence.

Reverence: The company raised $9.5 million of venture funding in a deal led by Target Global on May 10, 2022. The company is a developer of a digital health platform intended to manage complex home-bound care more consistently.

Rensair: The company raised $7 million of Series A venture funding in a deal led by Hoxton Ventures on May 10, 2022. The company is a developer of portable hospital-grade air purifiers.

Cessation Therapeutics: The company raised $5.8 million of venture funding from JDH Investment Management and other undisclosed investors on May 11, 2022. The company is a developer of novel vaccines designed to address addiction dependency.

evolvedMD: The company raised $5.4 million of Series A venture funding from Waterline Ventures and Conductive Ventures on May 10, 2022. The company is a provider of services intended to innovate and lead the integration of behavioral health in modern primary care.

Kypha: The company raised $5.2 million of venture funding from undisclosed investors on May 12, 2022. The company is a developer in-vitro diagnostic biomarker tests intended to monitor immune system activity.

Agile Occupational Medicine: The company received an undisclosed amount of development capital from Angeles Equity Partners on May 11, 2022. The company is an operator of occupational healthcare clinics intended to deliver care and professional treatment for injured workers.

Biolog: The company raised an undisclosed amount of venture funding from BroadOak Capital Partners and Research Corporation Technologies on May 12, 2022. The company is a developer of cell analysis tools designed to identify cell phenotypes for early-stage detection of diseases.

Sensio Air: The company raised an undisclosed amount of venture funding from Daikin Industries on May 11, 2022. The company is a developer of a smart allergen tracker designed to improve indoor air quality.

Validant: The company received an undisclosed amount of development capital from GHO Capital, Goldman Sachs Asset Management, Los Angeles County Employees’ Retirement Association and its management on May 10, 2022. The company is a provider of compliance and regulatory affairs consulting services to pharmaceutical, biologics, medical device and diagnostics manufacturers.

---

Biohaven Pharmaceutical / Pfizer: The company reached a definitive agreement to be acquired by Pfizer for $11.6 billion on May 10, 2022. Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company.

Intersect ENT / Medtronic: The company was acquired by Medtronic for $1.1 billion on May 13, 2022. Intersect ENT Inc is a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions.

ModeX Therapeutics / OPKO Health: The company was acquired by OPKO Health for $300 million on May 9, 2022. The company is a manufacturer and developer of immune therapy drugs.

ProSomnus Sleep Technologies / Lakeshore Acquisition I: The company reached a definitive agreement to acquire Lakeshore Acquisition I through a reverse merger for $125 million, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol OSA on May 9, 2022. The transaction values the company at $168 million. The company is a manufacturer of oral appliances designed to treat obstructive sleep apnea (OSA).

Novosteo / Cortexyme: The company reached a definitive agreement to be acquired by Cortexyme for $120 million on May 10, 2022. The company is a developer of a drug discovery platform designed to reduce the morbidity, mortality, and loss of productivity associated with bone fractures.

Sunosi / Axsome Therapeutics: The company, a subsidiary of Jazz Pharmaceuticals, was acquired by Axsome Therapeutics for $53 million on May 9, 2022. The company is a manufacturer of a dopamine and norepinephrine inhibitor intended to improve wakefulness in adults with excessive daytime sleepiness.

Advocate Aurora Health / Atrium Health: The company reached a definitive agreement to be acquired by Atrium Health for an undisclosed amount on May 11, 2022. The company is a provider of integrated healthcare services intended to improve health care quality.

Exolis / Hoppen: The company was acquired by Hoppen for an undisclosed amount on May 12, 2022. The company is a developer of an online e-health platform designed to bridge the gap between doctors and patients.

Medsenic / Bone Therapeutics: The company reached a definitive agreement to acquire Bone Therapeutics through a reverse merger on May 12, 2022. The company is a developer of medical drugs intended to treat debilitating autoimmune diseases.

Tempest / Monument: The company reached a definitive agreement to be acquired by Monument (Clinics/Outpatient Services) for an undisclosed amount on May 11, 2022. The company is an operator of a lifestyle coaching platform intended to offer counseling sessions to people suffering from alcohol addiction.